

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

RHANSON@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3085

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 3, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

June 3, 2004

Date

Robert E. Hanson

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/715,329 entitled "METHODS AND COMPOSITIONS FOR TAGGING VIA AZIDO SUBSTRATES" – Yingming Zhao and John R. Falck*
Our reference: UTSD:1489US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A5, B1, and C1-C16.


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:1489US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Robert E. Hanson
Reg. No. 42,628

REH/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Application of:
Yingming Zhao
John R. Falck

Serial No.: 10/715,329


Filed: November 17, 2003

For: METHODS AND COMPOSITIONS FOR
TAGGING VIA AZIDO SUBSTRATES

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:1489US

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
June 3, 2004	
Date	Robert E. Hanson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:1489US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 3, 2004

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:1489US

Serial No.

10/715,329

List of Patents and Publications for Applicant's

Applicant

Yingming Zhao

John R. Falck

INFORMATION DISCLOSURE STATEMENT

Filing Date:

November 17, 2003

Group:

1645

(Use several sheets if necessary)

U.S. Patent Documents


See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0016003	2/7/02	Saxon and Bertozzi	435	441	3/16/01
	A2	5,932,432	8/31/99	Crowell <i>et al.</i>	435	15	1/21/97
	A3	5,952,473	9/14/99	Cohen and Niewenhuizen	530	388.1	10/16/97
	A4	6,284,910	9/4/01	Spielmann <i>et al.</i>	558	152	12/15/99
	A5	6,492,128	12/10/02	Haklai <i>et al.</i>	435	7.2	2/26/98

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 1996006609	3/7/96	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Baron <i>et al.</i> , "RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody," <i>Proc. Natl. Acad. Sci., USA</i> , 97:11626-11631, 2000.
	C2	Brems and Rilling, "Photoaffinity labeling of the catalytic site of prenyltransferase," <i>Biochemistry</i> , 18:860-864, 1979.
	C3	Chehade <i>et al.</i> , "Photoaffinity analogues of farnesyl pyrophosphate transferable by protein farnesyl transferase," <i>J. Am. Chem. Soc.</i> , 124(8):8206-8219, 2002.
	C4	Chin <i>et al.</i> , "An expanded eukaryotic genetic code," <i>Science</i> , 301:964-967, 2003.
	C5	End <i>et al.</i> , "Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro," <i>Cancer Res.</i> , 61:131-137, 2001.
	C6	Gibbs <i>et al.</i> , "Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation," <i>J. Med. Chem.</i> , 42:3800-3808, 1999.

25371650.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:1489US

Serial No.

10/715,329

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Yingming Zhao

John R. Falck

Filing Date:

November 17, 2003

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	Gololobov and Kasukhin, "Recent advances in the Staudinger reaction," <i>Tetrahedron</i> , 48:1353-1406, 1992.
	C8	Holmes, "Model studies for new o-nitrobenzyl photolabile linkers: substituent effects on the rates of photochemical cleavage," <i>J. Org. Chem.</i> , 62:2370-2380, 1997.
	C9	Kiick <i>et al.</i> , "Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation," <i>Proc. Natl. Acad. Sci., USA</i> , 99:19-24, 2002.
	C10	Lin <i>et al.</i> , "Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies," <i>J. Gen. Virol.</i> , 80:91-96, 1999.
	C11	McGuire and Sebt, "Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity," <i>Oncogene</i> , 14:305-312, 1997.
	C12	Melkonian <i>et al.</i> , "Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated," <i>J. Biol. Chem.</i> , 274(6):3910-3917, 1999.
	C13	Saxon <i>et al.</i> , "Investigating cellular metabolism of synthetic azidosugars with the Staudinger ligation," <i>J. Am. Chem. Soc.</i> , 124:14893-14902, 2002.
	C14	Tamanoi <i>et al.</i> , "Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells," <i>Cell Mol. Life Sci.</i> , 58:1636-1649, 2001.
	C15	Tamanoi <i>et al.</i> , "Farnesylated proteins and cell cycle progression," <i>J. Cel Biochem.</i> , 37:64-70, 2001.
	C16	Tsuda <i>et al.</i> , "Stereospecific sythesis of a novel farnesyl protein transferase inhibitor, valinoctin A and its analogues," <i>J. Antibiot</i> , 49(10):1031-1035, 1996.

25371650.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.